Exercise Intensity, Duration Can Affect CKD Risk in Obesity, Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 7, 2024 -- For adults with overweight/obesity and type 2 diabetes (T2D), longer duration of moderate-to-vigorous physical activity (MVPA) and increases in MVPA are associated with a reduced risk for progression to chronic kidney disease (CKD), according to a study published online Feb. 6 in the British Journal of Sports Medicine.
Mengyi Liu, from Nanfang Hospital in Guangzhou, China, and colleagues examined the long-term association of objectively measured MVPA and its longitudinal changes with progression to CKD in patients with T2D and overweight/obesity in a study including 1,746 participants. MVPA was measured at baseline and years 1, 4, and 8.
In total, 567 participants experienced progression to CKD during a median follow-up of 12.0 years. The researchers observed a linear inverse association of cumulative average total MVPA and MVPA accumulated in bouts of ≥10 minutes with progression to CKD (per 100 minutes/week higher amount: hazard ratios, 0.91 and 0.81, respectively). From baseline to year 4, an increase in total MVPA (fourth quartile; ≥63.2 minutes/week) was associated with a reduced risk for progression to CKD compared with the largest reduction in MVPA (<−198.3 minutes/week; hazard ratio, 0.67).
"Our study has important public health implications because it suggests that maintaining a high level of MVPA, regardless of length of the bout, may have renal benefit for adults with overweight/obesity and T2D, especially for individuals who are unwilling or unable to engage in PA bouts that are ≥10min in duration," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Greater Reduction Seen in Mortality With Bariatric Surgery Than GLP-1 RAs
MONDAY, June 10, 2024 -- Bariatric metabolic surgery (BMS) is associated with a greater reduction in mortality than glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Overweight in Teens, Young Adults Tied to Cerebrovascular Disease in Women
THURSDAY, June 6, 2024 -- Being overweight in adolescence or early adulthood is associated with an increased risk for cerebrovascular disease among women, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.